References
Bhullar, K. S., Lagaron, N. O., McGowan, E. M., Parmar, I., Jha, A.,
Hubbard, B. P., & Rupasinghe, H. P. V. (2018). Kinase-targeted cancer
therapies: progress, challenges and future directions. Mol Cancer,
17 (1), 48. doi:10.1186/s12943-018-0804-2
Breen, M. E., & Soellner, M. B. (2015). Small molecule substrate
phosphorylation site inhibitors of protein kinases: approaches and
challenges. ACS chemical biology, 10 (1), 175-189.
doi:10.1021/cb5008376
Camidge, D. R., Pao, W., & Sequist, L. V. (2014). Acquired resistance
to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin
Oncol, 11 (8), 473-481. doi:10.1038/nrclinonc.2014.104
Cho, E. J., Devkota, A. K., Stancu, G., Edupunganti, R., Powis, G., &
Dalby, K. N. (2018). A Fluorescence-Based High-Throughput Assay for the
Identification of Anticancer Reagents Targeting
Fructose-1,6-Bisphosphate Aldolase. SLAS Discov, 23 (1), 1-10.
doi:10.1177/2472555217726325
Cox, K. J., Shomin, C. D., & Ghosh, I. (2011). Tinkering outside the
kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of
protein kinases. Future Med Chem, 3 (1), 29-43.
doi:10.4155/fmc.10.272
Fabbro, D. (2015). 25 years of small molecular weight kinase inhibitors:
potentials and limitations. Mol Pharmacol, 87 (5), 766-775.
doi:10.1124/mol.114.095489
Fasano, M., Della Corte, C. M., Califano, R., Capuano, A., Troiani, T.,
Martinelli, E., . . . Morgillo, F. (2014). Type III or allosteric kinase
inhibitors for the treatment of non-small cell lung cancer. Expert
Opin Investig Drugs, 23 (6), 809-821. doi:10.1517/13543784.2014.902934
Force, T., & Kolaja, K. L. (2011). Cardiotoxicity of kinase inhibitors:
the prediction and translation of preclinical models to clinical
outcomes. Nat Rev Drug Discov, 10 (2), 111-126.
doi:10.1038/nrd3252
Garuti, L., Roberti, M., & Bottegoni, G. (2010). Non-ATP competitive
protein kinase inhibitors. Curr Med Chem, 17 (25), 2804-2821.
doi:10.2174/092986710791859333
Gross, S., Rahal, R., Stransky, N., Lengauer, C., & Hoeflich, K. P.
(2015). Targeting cancer with kinase inhibitors. The Journal of
Clinical Investigation, 125 (5), 1780-1789. doi:10.1172/JCI76094
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G.
(2013). Cancer drug resistance: an evolving paradigm. Nat Rev
Cancer, 13 (10), 714-726. doi:10.1038/nrc3599
Hook, K. E., Garza, S. J., Lira, M. E., Ching, K. A., Lee, N. V., Cao,
J., . . . Pavlicek, A. (2012). An integrated genomic approach to
identify predictive biomarkers of response to the aurora kinase
inhibitor PF-03814735. Mol Cancer Ther, 11 (3), 710-719.
doi:10.1158/1535-7163.MCT-11-0184
Huang, D., Zhou, T., Lafleur, K., Nevado, C., & Caflisch, A. (2010).
Kinase selectivity potential for inhibitors targeting the ATP binding
site: a network analysis. Bioinformatics, 26 (2), 198-204.
doi:10.1093/bioinformatics/btp650
Kang, M. H., Smith, M. A., Morton, C. L., Keshelava, N., Houghton, P.
J., & Reynolds, C. P. (2011). National Cancer Institute pediatric
preclinical testing program: model description for in vitro cytotoxicity
testing. Pediatr. Blood Cancer, 56 (2), 239-249.
doi:10.1002/pbc.22801 [doi]
Kim, Y. H., Girard, L., Giacomini, C. P., Wang, P., Hernandez-Boussard,
T., Tibshirani, R., . . . Pollack, J. R. (2006). Combined microarray
analysis of small cell lung cancer reveals altered apoptotic balance and
distinct expression signatures of MYC family gene amplification.Oncogene, 25 (1), 130-138. doi:10.1038/sj.onc.1208997
Kufareva, I., & Abagyan, R. (2008). Type-II kinase inhibitor docking,
screening, and profiling using modified structures of active kinase
states. J Med Chem, 51 (24), 7921-7932. doi:10.1021/jm8010299
Mohiuddin, I. S., & Kang, M. H. (2019). DNA-PK as an Emerging
Therapeutic Target in Cancer. Front Oncol, 9 , 635.
doi:10.3389/fonc.2019.00635
Mohiuddin, I. S., Wei, S. J., & Kang, M. H. (2020). Role of OCT4 in
cancer stem-like cells and chemotherapy resistance. Biochim
Biophys Acta Mol Basis Dis, 1866 (4), 165432.
doi:10.1016/j.bbadis.2019.03.005
Mollaoglu, G., Guthrie, M. R., Bohm, S., Bragelmann, J., Can, I.,
Ballieu, P. M., . . . Oliver, T. G. (2017). MYC Drives Progression of
Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with
Vulnerability to Aurora Kinase Inhibition. Cancer Cell, 31 (2),
270-285. doi:10.1016/j.ccell.2016.12.005
Niederst, M. J., & Engelman, J. A. (2013). Bypass mechanisms of
resistance to receptor tyrosine kinase inhibition in lung cancer.Sci Signal, 6 (294), re6. doi:10.1126/scisignal.2004652
Owonikoko, T. K., Nackaerts, K., Csoszi, T., Ostoros, G., Baik, C.,
Mark, Z., . . . Spigel, D. R. (2016). 1423O - Randomized phase 2 study
of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) +
paclitaxel (P) vs placebo + P as second line therapy for small-cell lung
cancer (SCLC). Annals of Oncology, 27 , vi493.
doi:https://doi.org/10.1093/annonc/mdw389.01
Panicker, R. C., Chattopadhaya, S., Coyne, A. G., & Srinivasan, R.
(2019). Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors.Adv Exp Med Biol, 1163 , 253-278.
doi:10.1007/978-981-13-8719-7_11
Roskoski, R., Jr. (2020). Properties of FDA-approved small molecule
protein kinase inhibitors: A 2020 update. Pharmacol Res, 152 ,
104609. doi:10.1016/j.phrs.2019.104609
Sos, M. L., Dietlein, F., Peifer, M., Schottle, J., Balke-Want, H.,
Muller, C., . . . Thomas, R. K. (2012). A framework for identification
of actionable cancer genome dependencies in small cell lung cancer.Proc Natl Acad Sci U S A, 109 (42), 17034-17039.
doi:10.1073/pnas.1207310109
Tam, W. L., & Weinberg, R. A. (2013). The epigenetics of
epithelial-mesenchymal plasticity in cancer. Nat Med, 19 (11),
1438-1449. doi:10.1038/nm.3336
Wei, S. J., Nguyen, T. H., Yang, I. H., Mook, D. G., Makena, M. R.,
Verlekar, D., . . . Kang, M. H. (2020). MYC transcription activation
mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated
differentiation in neuroblastoma. Cell Death Dis, 11 (5), 368.
doi:10.1038/s41419-020-2563-4
Wilson, L. J., Linley, A., Hammond, D. E., Hood, F. E., Coulson, J. M.,
MacEwan, D. J., . . . Prior, I. A. (2018). New Perspectives,
Opportunities, and Challenges in Exploring the Human Protein Kinome.Cancer Res, 78 (1), 15-29. doi:10.1158/0008-5472.CAN-17-2291
Zhang, C., Ryu, Y. K., Chen, T. Z., Hall, C. P., Webster, D. R., &
Kang, M. H. (2012). Synergistic activity of rapamycin and dexamethasone
in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle
arrest and apoptosis. Leuk. Res, 36 (3), 342-349.
doi:S0145-2126(11)00520-0 [pii];10.1016/j.leukres.2011.10.022
[doi]
Zhang, J., Yang, P. L., & Gray, N. S. (2009). Targeting cancer with
small molecule kinase inhibitors. Nat Rev Cancer, 9 (1), 28-39.
doi:10.1038/nrc2559
Zhang, Y., Chang, F. M., Huang, J., Junco, J. J., Maffi, S. K., Pridgen,
H. I., . . . Wei, S. J. (2014). DSSylation, a novel protein modification
targets proteins induced by oxidative stress, and facilitates their
degradation in cells. Protein Cell, 5 (2), 124-140.
doi:10.1007/s13238-013-0018-8